Market Overview
The Global "Clinical Microbiology Market" is expected to grow at a high CAGR of 6.2% during the forecasting period (2021 - 2028).
Clinical microbiology focuses on all aspects of patient infections from testing samples to identifying bacterial, viral, fungal, and parasitic agents that are contributing to the infectious process, determining the susceptibility of microorganisms to various antimicrobial agents, and reporting the results to healthcare providers.
The adaptation of microbiological techniques to the study of the etiological agents of infectious disease. Clinical microbiology determines the nature of the infectious disease and tests the ability of various antibiotics to inhibit or kill the isolated microorganisms. In addition to bacteriology, a contemporary clinical microbiologist is responsible for a wide range of microscopic and cultural studies in mycology, parasitology, and virology. The clinical microbiology is often the most competent person available to determine the nature and extent of hospital-acquired infections, as well as public-health problems that affect both the hospital and the community.
Download free sample: https://www.datamintelligence.com/download-sample/clinical-microbiology-market
Market Dynamics:
The market is driven is the rising infectious diseases that are primarily diagnosed using clinical tests. According to the Centers for Disease Control and Prevention (CDC), around 9,421 new cases of tuberculosis, 51,455 new cases of salmonella, 33,461 new cases of Lyme disease, and 433 new cases of meningococcal disease were registered in the U.S. in 2014.
Similarly, according to the American Cancer Society, around 1,688,780 new cases of cancer were diagnosed in the U.S. in 2017. Thus, the high prevalence of diseases where clinical tests are used as one of the major diagnostic tools is expected to augment market growth in the future. Sudden outbreaks of Ebola, Zika, and other contagious pathogens are also contributing to the rising prevalence of infectious diseases. As per an article published in the Journal of Clinical Microbiology, there is a shortage of trained and skilled professionals in medical and microbiological laboratories for processing and interpreting samples and specimens. Moreover, there has been a steep decline in the number of medical laboratory training programs and students graduating from such programs in the U.S.
As high-income countries are stepping up their pursuit of countering hospital-acquired infections, middle- and low-income countries are recognizing the threat. The introduction of automated systems and innovative designs is expected to intensify market competition and change market dynamics over the forecast period. This factor is driving the growth of the market in the forecast period.
The World Health Organization (WHO) is particularly active in countries such as Ethiopia, Burkina Faso, Nigeria, Algeria, and Senegal, where the occurrence of HAIs ranged between 2.5% and 14.8%. This has led to increased demand for HAI diagnostics in these countries. Countries such as India, Sri Lanka, Pakistan, and Bhutan are also actively participating in HAI awareness programs. India and China are projected to be the main countries driving demand for HAI diagnostics instruments and tests in the future. This factor is also driving the growth of the market in the forecast period.
Similarly, factors like the consolidation of diagnostic laboratory chains and the increase in public awareness are driving the growth of the market. The emerging countries are expected to outperform the U.S. and European countries. This is mainly due to the increase in the major hospital chains opening new centers in major cities as well as an increase in government expenditure.
However, Clinical microbiology testing procedures are not adequately reimbursed across several countries such as India, China, and other emerging countries in the Middle East and Africa, which have a high target patient population base. This is a major factor that limits the preference for clinical microbiology products among patients and healthcare professionals. This directly affects the adoption of premium-priced clinical microbiology products, thereby negatively affecting their market growth in the forecast period.
The recent outbreak of the COVID-19 pandemic is negatively affecting the growth of the market as the laboratories are busy with the COVID-19 test which has halted all other tests. This factor will hinder the growth of the market in the forecast period.
Segment Analysis
– By Product Type
· Reagents *
· Laboratory Instruments
· Automated Culture Systems
– By Application
· Respiratory Diseases
· Bloodstream Infections,
· Gastrointestinal Diseases
· Others
Geographical Presentation
By region, the global clinical microbiology market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global surgical glue market and is expected to grow at the highest CAGR during the forecast period due to an increase in the burden of COVID-19, well-developed health care infrastructure, and increasing prevalence of chronic obstructive pulmonary diseases, flu diseases, whooping cough, and other respiratory infections. This is anticipated to augment the Respiratory infectious disease treatment market in the region. COPD is considered to be the third-leading cause of death in the U.S., and the fourth-leading cause of death across the world. According to an article published on Very well Health, COPD affects around 11 million people in the U.S. and occurs in people over the age of 40. These statistics drive the demand for the treatment of respiratory infectious diseases. This factor will drive the growth of the market in the region.
Europe was the second-largest market for respiratory infectious diseases followed by the Asia Pacific, owing to the rising prevalence of COPD disease in the region. For instance, according to the European Respiratory Nurses Association (ERNA), 259,000 people die of COPD each year in the EU. Moreover, rising cases of COVID 19 in Italy, Spain, the U.K., and other countries across Europe are boosting the need for treatment of respiratory infectious diseases across the region.
The market in the Asia Pacific is anticipated to expand at a rapid pace during the forecast period, owing to the COVID-19 pandemic and key players involved in manufacturing generic drugs for the treatment of the disease. This factor will drive the growth of the market in the region.
Competitive Analysis
The global clinical microbiology market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market bioMérieux SA, Danaher Corporation, Becton, Dickinson and Company, Abbott Laboratories, Bio-Rad Laboratories, Inc, F. Hoffmann-La Roche AG, Bruker Corporation, Hologic, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc. are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.
The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for clinical microbiology across the globe.
For instance, in 2017, bioMérieux held the leading position in the global clinical microbiology market. The company has a robust product portfolio and a strong geographical presence in more than 150 countries across the world. To maintain its leadership position in the market, the company has been focusing on R&D activities and new product launches.
In 2017, Hologic (US) collaborated with Seegene Inc. (South Korea) to develop and supply highly multiplexed real-time PCR reagents and assays for Hologic's Panther Fusion platform.
View Full Report: https://www.datamintelligence.com/research-report/clinical-microbiology-market
Enquiry Before Buying: https://www.datamintelligence.com/enquiry/clinical-microbiology-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com
According to research report the clinical microbiology market is expected to reach USD 4.95 billion by 2023 from USD 3.63 billion in 2018 growing at a CAGR of 6.4% during forecast period.
Growth in clinical microbiology market can be attributed to factors such as rising incidence of infectious diseases and growing outbreak of epidemics and increased funding and public-private investments.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219135367Market Size EstimationA detailed market estimation approach was followed to estimate and validate the size of the clinical microbiology market and other dependent submarkets, as mentioned above.
The key players in the clinical microbiology market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research.
Research methodology includes the study of the annual and quarterly financial reports of the top market players as well as interviews with industry experts for key insights (both quantitative and qualitative trends) on the clinical microbiology market.
All percentage shares, splits, and breakdowns were determined by using secondary sources and verified through primary sources.
The global clinical microbiology market is segmented by product, disease area, end user, and region.
